Remote ischemic preconditioning (RIPC) has emerged as a procedure for different organs protection against acute ischemia/reperfusion injury as is shown by different clinical trials. Although most studies have been conducted in patients undergoing coronary artery by-pass grafting and valvular heart surgery, also were observed protective effect in other organs as kidneys, intestine and others. RIPC is an innate and powerful mechanism where a tissue or organ is exposed to a transient episode of ischemia-reperfusion and then confer a global resistance to subsequent episodes of ischemia in remote organs. However the potential mechanism through which RIPC works is unclear. The signal transfer to organs is through humoral, neuronal and systemic communications, which activate specific receptors, intracellular kinases and mitochondrial function. Recently has been reported that limb RIPC attenuates intestinal and pulmonary injury after abdominal aortic aneurysm repair and also after pulmonary resection, where they found significant decreases in serum malondialdehyde in treated group with RIPC.